SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
E.M. Ciruelos1, X. González-Farré2, A. Perelló3, E. Alba4, P. Palacios-Ozores5, J. Salvador-Bofil6, M. Merino7, P. Villagrasa8, P. Celiz8, T. Pascual8, A. Prat9, S. Pernas Simon10
Comunicaciones en congresos
Poster de resultados
ESMO BREAST
2020
